In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
The article provides an in-depth analysis of 29 analyst recommendations for Biomarin Pharmaceutical (NASDAQ:BMRN) over the past three months. Analysts have varied opinions, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $99.79, a decrease from the previous $106.14. The article also highlights Biomarin's financial performance, including a 19.61% revenue growth rate and strong profitability metrics.
October 30, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biomarin Pharmaceutical (NASDAQ:BMRN) has received mixed analyst ratings, with a decrease in the average 12-month price target to $99.79. Despite this, the company shows strong financial performance with a 19.61% revenue growth rate and high profitability metrics.
The mixed analyst ratings and lowered price target suggest a neutral short-term impact on BMRN's stock price. However, the company's strong financial performance, including significant revenue growth and profitability, may offset some of the negative sentiment from the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100